In vitro and in vivo evaluation of a sustained-release once-a-day formulation of the novel antihypertensive drug MT-1207

References

• Abd-Elbary A, Haider M, Sayed S. 2012. In vitro characterization and release study of Ambroxol hydrochloride matrix tablets prepared by direct compression. Pharm Dev Technol. 17(5):562–573.
   PubMed Web of Science ®Google Scholar
• Alaux G, Andre F, Lewis G. inventors; Synthelabo SA, assignee. 2000. Jun 07. Controlled-release dosage forms comprising a short acting hypnotic or a salt. European patent EP 1005863.
   Google Scholar
• Aulton ME, Taylor KMG, editors. 2017. Aulton's Pharmaceutics: the design and manufacture of medicines. 5th ed. Edinburgh: Elsevier.
   Google Scholar
• Baghel S, Cathcart H, O'Reilly NJ. 2016. Polymeric amorphous solid dispersions: a review of amorphization, crystallization, stabilization, solid-state characterization, and aqueous solubilization of biopharmaceutical classification system class II drugs. J Pharm Sci. 105(9):2527–2544.
   PubMed Web of Science ®Google Scholar
• Baka E, Comer JE, Takacs-Novak K. 2008. Study of equilibrium solubility measurement by saturation shake-flask method using hydrochlorothiazide as model compound. J Pharm Biomed Anal. 46(2):335–341.
   PubMed Web of Science ®Google Scholar
• Boxenbaum H. 1982. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm. 10(2):201–227.
   PubMedGoogle Scholar
• Carr R. 1965b. Evaluating flow properties of solids. Chem Eng. 72:163–168.
   Google Scholar
• Chowhan ZT. 1980. Role of binders in moisture-induced hardness increase in compressed tablets and its effect on in vitro disintegration and dissolution. J Pharm Sci. 69(1):1–4.
   PubMed Web of Science ®Google Scholar
• Chu K, Lee E, Jeong S, Park ES. 2012. Effect of particle size on the dissolution behaviors of poorly water-soluble drugs. Arch Pharm Res. 35(7):1187–1195.
   PubMed Web of Science ®Google Scholar
• Defang O, Shufang N, Wei L, Hong G, Hui L, Weisan P. 2005. In vitro and in vivo evaluation of two extended release preparations of combination metformin and glipizide. Drug Dev Ind Pharm. 31(7):677–685.
   PubMed Web of Science ®Google Scholar
• Dipti Phadtare GP, Nilesh B, Asawat M. 2014. Hypromellose – a choice of polymer in extended release tablet formulation. World J Pharm Pharm Sci. 3(9):551–566.
   Google Scholar
• Dürig T, Fassihi AR. 1993. Identification of stabilizing and destabilizing effects of excipient-drug interactions in solid dosage form design. Int J Pharm. 97(1-3):161–170.
   Web of Science ®Google Scholar
• [EMA] European Medicines Agency 2010. CPMP/EWP/QWP/1401/98 Rev. 1/Corr Guideline on the Investigation of Bioequivalence. London.
   Google Scholar
• Emara LH, Taha NF, Badr RM, Mursi NM. 2012. Development of an osmotic pump system for controlled delivery of diclofenac sodium. Drug Discov Ther. 6(5):269–277.
   PubMedGoogle Scholar
• Gao P, Skoug JW, Nixon PR, Ju TR, Stemm NL, Sung KC. 1996. Swelling of hydroxypropyl methylcellulose matrix tablets. 2. Mechanistic study of the influence of formulation variables on matrix performance and drug release. J Pharm Sci. 85(7):732–740.
   PubMed Web of Science ®Google Scholar
• Hausner H. 1967. Friction condition in a mass of metal powders. Int J Powder Metall. 3:7–13.
   Google Scholar
• Hiremath P, Saha R. 2008. Controlled release hydrophilic matrix tablet formulations of isoniazid: design and in vitro studies. AAPS PharmSciTech. 9(4):1171–1178.
   PubMed Web of Science ®Google Scholar
• Hutton JT, Morris JL. 1992. Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease. Neurology. 42(1 Suppl 1):51–56.
   PubMed Web of Science ®Google Scholar
• Jamzad S, Fassihi R. 2006. Development of a controlled release low dose class II drug-Glipizide. Int J Pharm. 312(1-2):24–32.
   PubMed Web of Science ®Google Scholar
• Jamzad S, Fassihi R. 2007. Development of a robust once-a-day glipizide matrix system. J Pharm Pharmacol. 59(6):769–775.
   PubMed Web of Science ®Google Scholar
• Jinno JI, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, Toguchi H, Liversidge GG, Higaki K, Kimura T. 2006. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release. 111(1-2):56–64.
   PubMed Web of Science ®Google Scholar
• Katzung BG, Masters SB, Trevor AJ, editors. 2012. Basic and clinical pharmacology. London: McGraw-Hill Medical.
   Google Scholar
• Klein E. 2002. The role of extended-release benzodiazepines in the treatment of anxiety: a risk-benefit evaluation with a focus on extended-release alprazolam. J Clin Psychiatry. 63(Suppl 14):27–33.
   PubMed Web of Science ®Google Scholar
• Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. 1983. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 15(1):25–35.
   Web of Science ®Google Scholar
• Loh ZH, Samanta AK, Sia Heng PW. 2015. Overview of milling techniques for improving the solubility of poorly water-soluble drugs. Asian J Pharm Sci. 10(4):255–274.
   Web of Science ®Google Scholar
• Malinovskaja K, Laaksonen T, Kontturi K, Hirvonen J. 2013. Ion-exchange and iontophoresis-controlled delivery of apomorphine. Eur J Pharm Biopharm. 83(3):477–484.
   PubMed Web of Science ®Google Scholar
• Marinko N, Zámostný P. 2020. Meloxicam carrier systems having enhanced release and aqueous wettability prepared using micro-suspensions in different liquid media. AAPS PharmSciTech. 21(5):155.
   PubMed Web of Science ®Google Scholar
• McCarberg B. 2007. Tramadol extended-release in the management of chronic pain. Ther Clin Risk Manag. 3(3):401–410.
   PubMedGoogle Scholar
• Melia CD. 1991. Hydrophilic matrix sustained release systems based on polysaccharide carriers. Crit Rev Ther Drug Carrier Syst. 8(4):395–421.
   PubMed Web of Science ®Google Scholar
• Merchant HA, Shoaib HM, Tazeen J, Yousuf RI. 2006. Once-daily tablet formulation and in vitro release evaluation of cefpodoxime using hydroxypropyl methylcellulose: a technical note. AAPS PharmSciTech. 7(3):78
   PubMed Web of Science ®Google Scholar
• Michel M. 2002. A benefit-risk assessment of extended-release oxybutynin. Drug Saf. 25(12):867–876.
   PubMed Web of Science ®Google Scholar
• Michelson EL. 1991. Calcium antagonists in cardiology: Update on sustained-release drug delivery systems. Clin Cardiol. 14(12):947–950.
   PubMed Web of Science ®Google Scholar
• Mills TK, Bundy DJ, Kelly NT, Reed EJ, Kearney MP, Reynolds MK, Chen J, He J. 2016. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 134(6):441–450.
   PubMed Web of Science ®Google Scholar
• Mura P, Faucci MT, Manderioli A, Bramanti G, Ceccarelli L. 1998. Compatibility study between ibuproxam and pharmaceutical excipients using differential scanning calorimetry, hot-stage microscopy and scanning electron microscopy. J Pharm Biomed Anal. 18(1-2):151–163.
   PubMed Web of Science ®Google Scholar
• Mura P, Manderioli A, Bramanti G, Furlanetto S, Pinzauti S. 1995. Utilization of differential scanning calorimetry as a screening technique to determine the compatibility of ketoprofen with excipients. Int J Pharm. 119(1):71–79.
   Web of Science ®Google Scholar
• Nair AB, Vyas H, Kumar A. 2010. Controlled release matrix uncoated tablets of enalapril maleate using HPMC alone. J Basic Clin Pharm. 1(2):71–75.
   PubMedGoogle Scholar
• Nguyen TT, Hwang KM, Kim SH, Park ES. 2020. Development of novel bilayer gastroretentive tablets based on hydrophobic polymers. Int J Pharm. 574(118865):1–11.
   Google Scholar
• Pani NR, Nath LK, Acharya S. 2011. Compatibility studies of nateglinide with excipients in immediate release tablets. Acta Pharm. 61(2):237–247.
   PubMed Web of Science ®Google Scholar
• Peppas N. 1985. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv. 60(4):110–111.
   PubMedGoogle Scholar
• Pieper JA. 2002. Understanding niacin formulations. Am J Manag Care. 8(12 Suppl):S308–S314.
   PubMed Web of Science ®Google Scholar
• Prakash A, Markham A. 1999. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease. Drugs. 57(3):383–408.
   PubMed Web of Science ®Google Scholar
• Rowe RC, Sheskey PJ, Quinn ME, editors. 2009. Handbook of pharmaceutical excipients. 6th edition. London: APhA/Pharmaceutical Press.
   Google Scholar
• Saurí J, Millán D, Suñé-Negre JM, Colom H, Ticó JR, Miñarro M, Pérez-Lozano P, García-Montoya E. 2014. Quality by Design approach to understand the physicochemical phenomena involved in controlled release of captopril SR matrix tablets. Int J Pharm. 477(1-2):431–441.
   PubMed Web of Science ®Google Scholar
• Savaşer A, Taş C, Bayrak Z, Özkan CK, Özkan Y. 2013. Effect of different polymers and their combinations on the release of metoclopramide HCl from sustained-release hydrophilic matrix tablets. Pharm Dev Technol. 18(5):1122–1130.
   PubMed Web of Science ®Google Scholar
• Shargel L, Wu-Pong S, Yu ABC, editors. 2012. Applied biopharmaceutics and pharmacokinetics. 6th edition. New York (NY): McGraw-Hill.
   Google Scholar
• Shergill M, Patel M, Khan S, Bashir A, McConville C. 2016. Development and characterisation of sustained release solid dispersion oral tablets containing the poorly water soluble drug disulfiram. Int J Pharm. 497(1-2):3–11.
   PubMed Web of Science ®Google Scholar
• Siepmann J, Peppas NA. 2001. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev. 48(2-3):139–157.
   PubMed Web of Science ®Google Scholar
• Simon S. 2005. Opioids and treatment of chronic pain: understanding pain patterns and the role for rapid-onset opioids. Med Gen Med. 7(4):54.
   PubMedGoogle Scholar
• Smith A. 1982. Use of thermal analysis in predicting drug-excipient interactions. Anal Proc. 19:559–561.
   Google Scholar
• Tsioufis C, Thomopoulos C. 2017. Combination drug treatment in hypertension. Pharmacol Res. 125(Pt B):266–271.
   PubMed Web of Science ®Google Scholar
• [USP] United States Pharmacopeial Convention 2012a. United States Pharmacopeia <1174> Powder Flow. Rockville (MD).
   Google Scholar
• [USP] United States Pharmacopeial Convention 2012b. United States Pharmacopeia <1216> Tablet Friability. Rockville (MD).
   Google Scholar
• [USP] United States Pharmacopeial Convention 2012c. United States Pharmacopeia <1217> Tablet Breaking Force. Rockville (MD).
   Google Scholar
• [USP] United States Pharmacopeial Convention 2015. United States Pharmacopeia <616> Bulk Density and Tapped Density of Powders. Rockville (MD).
   Google Scholar
• [USP] United States Pharmacopeial Convention 2016. United States Pharmacopeia <905> Uniformity of Dosage Units. Rockville (MD).
   Google Scholar
• [USP] United States Pharmacopeial Convention 2017. United States Pharmacopeia <467> Residual Solvents. Rockville (MD).
   Google Scholar
• Wagstaff AJ, Goa KL. 2001. Once-weekly fluoxetine. Drugs. 61(15):2221–2228.
   PubMed Web of Science ®Google Scholar
• Wen H, Park K, editors. 2010. Oral controlled release formulation design and drug delivery: theory to practice. Hoboken (NJ): Wiley
   Google Scholar
• Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, et al.; ESC Scientific Document Group. 2018. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 39(33):3021–3104.
   PubMed Web of Science ®Google Scholar